Petitioner seeks Centre’s inquiry report to be placed on record in HC
Bhiwani Sudhar and Vikas Samiti, alleging illegal purchase of Raxil-2DS fungicide worth several crores of rupees by the Haryana government, has sought directions from the Punjab and Haryana high court to place on court record a copy of inquiry by central government in the case.punjab Updated: May 07, 2014 11:12 IST
Bhiwani Sudhar and Vikas Samiti, alleging illegal purchase of Raxil-2DS fungicide worth several crores of rupees by the Haryana government, has sought directions from the Punjab and Haryana high court to place on court record a copy of inquiry by central government in the case.
Haryana IAS officer Ashok Khemka had questioned the usefulness of Raxil-2DS for treatment of Karnal Bunt disease in wheat crop.
It was on Tuesday that the petitioner organisation made a request before the division bench headed by justice AK Mittal.
In March, the parliamentary standing committee on agriculture had ordered a centre government probe in the case to find out propriety and legality of the state agriculture department of Haryana spending central money on RAXIL, a specific brand of Bayer Crop Science India, for unapproved treatment.
The central government had informed the high court earlier that Raxil-2DS was not approved by the Central Insecticide Board and Registration Committee (CIBRC) for control of Karnal Bunt disease.
The petitioner had earlier sought an independent probe into purchase of Raxil - 2 DS worth crores by state gover nment under Rashtriya Krishi Vikas Yojna from Bayer Crop Science India for wheat seed treatment including ‘Kar nal Bunt’.
It was informed that there is no credible scientific research that RAXIL or Tebuconazole controlled Karnal Bunt disease in wheat crop.
The petitioner had informed the court that fungicide was being purchased by state gover nment for wheat seed treatment from Bayer Crop Science India at an extra ordinary price of 1,342 per kg from October 2010 onwards, whereas better for mulations of same chemical were being exported to developed countries at much cheaper price by Indian Generic Manufacturers.
The court adjourned the case for next hearing to May 27.